Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival

Transplantation

Volumn 61, Issue 3, 1996, Pages 356-363

  Kaplon, Richard J ^a   Hochman, Paula S ^b   Michler, Robert E ^a   Kwiatkowski, Pawel A ^a   Edwards, Niloo M ^a   Berger, Carole L ^a,c   Xu, H E ^a   Meier, Werner ^b   Wallner, Barbara P ^b,d   Chisholm, Patricia ^b   Marboe, Charles C ^a,e  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b BIOGEN   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ImmuLogic Pharmaceutical Corporation   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABOON; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HEART GRAFT; HISTOPATHOLOGY; IMMUNOTHERAPY; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RECIPIENT; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD2; ANTIGENS, CD58; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; LYMPHOCYTE CULTURE TEST, MIXED; PAPIO; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TRANSPLANTATION, HETEROTOPIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 9044247848     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199602150-00004     Document Type: Article

References (36)

1. Linsley PS, Wallace PM, Johnson J, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992; 257: 792.
2. van Seventer GA, Shimizu Y, Shaw S. Roles of multiple accessory molecules in T-cell activation. Curr Opin Immunol 1991; 3: 294.
3. Moingeon P, Chang H, Wallner BP, Stebbins C, Frey AZ, Reinherz EL. CD2-mediated adhesion facilitates T lymphocyte recognition function. Nature 1989; 339: 312.
4. Damle NK, Klussman K, Linsley PS, Aruffo A. Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen primed CD4+ T lymphocytes. J Immunol 1992; 148: 1985.
5. Lenschow DJ, Zeng J, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992; 257: 789.
6. Killeen N, Moessner R, Arvieux J, Willis A, Williams AF. The MRC OX-45 antigen of rat leukocytes and endothelium is in a subset of the immunoglobulin family with CD2, LFA-3, and carcinoembryonic antigens. EMBO J 1988; 7: 3087.
7. Driscoll PC, Cyster JG, Campbell ID, Williams AF. Structure of domain-1 rat lymphocyte-T CD2 antigen. Nature 1991; 353: 762.
8. Seed B. An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2. Nature 1987; 329: 840.
9. Peterson A, Seed B. Monoclonal antibody and ligand binding sites of the T cell erythrocyte receptor (CD2). Nature 1987; 329: 842.
10. Miller GT, Hochman PS, Meier W, et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993; 178: 211.
11. Delmonico FL, Cosimi AB, Kawai T, et al. Nonhuman primate responses to murine and humanized OKT4A. Transplantation 1993; 55: 722.
12. Thompson KM. Human monoclonal antibodies. Immunol Today 1988; 9: 113.
13. Socha WW, Ruffle J. Blood groups in primates. Theory, practice, evolutionary meaning. Monographs in primatology, Vol 3. New York, 1983.
14. Kurlansky PA, Sadeghi AM, Michler RE, et al. Comparable survival of intra-species and cross-species primate cardiac transplants. Transplant Proc 1987; 19: 1067.
15. Michler RE, McManus RP, Smith CR, Sadeghi AN, Rose EA. Technique for primate heterotopic cardiac xenotransplantation. J Med Primatol 1985; 14: 357.
16. Pepinsky RB, Chen LL, Meier W, Wallner BP. The increased potency of cross-linked lymphocyte function-associated antigen 3 multimers is a direct consequence of changes in valency. J Biol Chem 1991; 266: 18244.
17. Parlevliet KJ, Schellekens PTA. Monoclonal antibodies in renal transplantation: a review. Transplant Int 1992; 5: 234.
18. Cosimi AB, Delmonico FL, Wright JK, et al. Prolonged survival of nonhuman primate renal allograft recipients treated only with anti-CD4 monoclonal antibody. Surgery 1990; 108: 406.
19. Rao PT, Olini G, Kille J, et al. OKT3E, an anti-CD3 antibody that does not elicit side effects or anti-idiotype responses in chimpanzees. Transplantation 1991; 52: 691.
20. Delmonico FL, Fuller TC, Russell PS, et al. Variation in patient response associated with different preparations of murine monoclonal antibody therapy. Transplantation 1989; 47: 92.
21. Bieber C, Howard F, Pennock J, et al. Preparation, characterization, and primate testing of monoclonal antithymocyte globulin. Transplantation 1981; 31: 283.
22. Jonker M, Goldstein G, Bainer H. Effects of in vivo administration of monoclonal antibodies specific for human T cell subpopulations on the immune system in a rhesus monkey model. Transplantation 1983; 35: 521.
23. Berlin PJ, Bacher JD, Sharrow SO, Gonzalez C, Gress RE. Monoclonal antibodies against human T cell adhesion molecules - modulation of immune function in nonhuman primates. Transplantation 1992; 53: 840.
24. Giorgi JV, Burton RC, Barrett LV, Delmonico FL, Goldstein G, Cosimi AB. Immunosuppressive effect and immunogenicity of OKT11A monoclonal antibody in monkey allograft recipients. Transplant Proc 1983; 15: 639.
25. Reimann KA, Turner S, Lambert JM, Reed MH, Schlossman SF, Letvin NL. In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. Transplantation 1989; 47: 92.
26. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993; 341: 1620.
27. Isaacs UJ, Watts R, Hazelman B, et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992; 340: 283.
28. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89: 11102.
29. Chisholm PL, Williams CA, Hones WE, et al. The effects of an immunomodulatory LFA3-IgG1 fusion protein on nonhuman primates. Ther Immunol 1994; 1: 205.
30. Wesselborg S, Janssen O, Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol 1993; 150: 4338.
31. Dyer M, Hale G, Hayhoe F, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73: 1431.
32. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. J Immunol 1994; 152: 2753.
33. Cosimi AB, Colvin RB, Jaffers GJ, et al. Immunologic monitoring of monoclonal antibody therapy: comparison of five antibodies as immunosuppressants of renal allograft rejection. Transplant Proc 1984; 16: 1459.
34. Cosimi AB, Conti D, Delmonico F, et al. In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. J Immunol 1990; 144: 4604.
35. Nakamura EK, McCabe SM, Zheng B, et al. Potent and effective prolongation by anti-LFA-1 monoclonal antibody monotherapy of non-primarily vascularized heart allograft survival in mice without T cell depletion. Transplantation 1993; 55: 412.
36. Paul LC, Davidoff A, Paul DW, Benediktsson H, Issekutz TB. Monoclonal antibodies against LFA-1 and VLA-4 inhibit graft vasculitis in rat cardiac allografts. Transplant Proc 1993; 25(1): 813.